Skip to main content
. 2022 Nov 3;2022(11):CD013403. doi: 10.1002/14651858.CD013403.pub2

NCT03712228.

Study name A study to investigate CSL312 in subjects with hereditary angioedema (HAE)
Methods Randomised, double‐blind, placebo‐controlled, multicentre trial
Participants Adults aged 18–65 years with C1‐INH HAE or FXII/PLG HAE
Interventions CSL312 (factor XIIa antagonist monoclonal antibody)
Placebo
Outcomes Number of HAE attacks, attack severity, pharmacokinetics, AEs
Starting date 29 October 2018
Contact information CSL Behring
Notes Anticipated completion date: 14 October 2021